James R. Kasinger
2020
In 2020, James R. Kasinger earned a total compensation of $2.6M as General Counsel at CRISPR Therapeutics AG, a 39% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $234,030 |
|---|---|
| Option Awards | $1,563,531 |
| Salary | $403,500 |
| Stock Awards | $379,695 |
| Other | $11,400 |
| Total | $2,592,156 |
Kasinger received $1.6M in option awards, accounting for 60% of the total pay in 2020.
Kasinger also received $234K in non-equity incentive plan, $403.5K in salary, $379.7K in stock awards and $11.4K in other compensation.
Rankings
In 2020, James R. Kasinger's compensation ranked 4,402nd out of 13,090 executives tracked by ExecPay. In other words, Kasinger earned more than 66.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,402 out of 13,090 | 66th |
Division Manufacturing | 1,785 out of 5,621 | 68th |
Major group Chemicals And Allied Products | 696 out of 2,254 | 69th |
Industry group Drugs | 595 out of 1,954 | 70th |
Industry Biological Products, Except Diagnostic Substances | 138 out of 411 | 66th |
Source: SEC filing on April 28, 2021.
Kasinger's colleagues
We found four more compensation records of executives who worked with James R. Kasinger at CRISPR Therapeutics AG in 2020.
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019